Title:
DETECTION OF EPHA3 AS A MARKER OF THE PRESENCE OF A SOLID TUMOR
Document Type and Number:
WIPO Patent Application WO/2011/160132
Kind Code:
A3
Abstract:
The disclosure provides methods and compositions for detecting non-hematopoietic, non-tumor EphA3-expressing cells in cancer patients and for monitoring the prognosis of patients using EphA3 as a detection marker. Specifically, the level of EphA3+ non- hematopoietic. non-tumor cells in the peripheral blood is used for diagnosing the presence of a solid tumor. The methods further comprise determining whether the EphA3+ cells express CD34, CD45, CD44, CD90, and/or KDR. Methods for treating patients having an increased level of EphA3-expressing non-hematopoietic, non-tumor cells in the blood are also described.
Inventors:
LACKMANN MARTIN (AU)
SCOTT ANDREW MARK (AU)
TO CATHERINE (AU)
BEBBINGTON CHRISTOPHER R (US)
YARRANTON GEOFFREY T (US)
BAER MARK (US)
PALATH VARGHESE (US)
SCOTT ANDREW MARK (AU)
TO CATHERINE (AU)
BEBBINGTON CHRISTOPHER R (US)
YARRANTON GEOFFREY T (US)
BAER MARK (US)
PALATH VARGHESE (US)
Application Number:
PCT/US2011/041114
Publication Date:
April 05, 2012
Filing Date:
June 20, 2011
Export Citation:
Assignee:
KALOBIOS PHARMACEUTICALS INC (US)
LACKMANN MARTIN (AU)
SCOTT ANDREW MARK (AU)
TO CATHERINE (AU)
BEBBINGTON CHRISTOPHER R (US)
YARRANTON GEOFFREY T (US)
BAER MARK (US)
PALATH VARGHESE (US)
LUDWIG INST CANCER RES (US)
MONASH UNIVERISTY (AU)
LACKMANN MARTIN (AU)
SCOTT ANDREW MARK (AU)
TO CATHERINE (AU)
BEBBINGTON CHRISTOPHER R (US)
YARRANTON GEOFFREY T (US)
BAER MARK (US)
PALATH VARGHESE (US)
LUDWIG INST CANCER RES (US)
MONASH UNIVERISTY (AU)
International Classes:
G01N33/53; A61K39/00; A61K39/395; C07K16/00; C12P19/34; G01N33/567
Foreign References:
| US20080286272A1 | 2008-11-20 |
Other References:
DUDA ET AL.: "A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood.", NAT PROTOC., vol. 2, no. 4, 2007, pages 805 - 810, XP009176565
VEARING ET AL.: "Concurrent Binding of Anti-EphA3 Antibody and Ephrin-A5 Amplifies EphA3 Signaling and Downstream Responses: Potential as EphA3-Specific Tumor-Targeting Reagents.", CANCER RES., vol. 65, no. 15, 1 August 2005 (2005-08-01), pages 6745 - 6754, XP002493162
O'CONNOR ET AL.: "Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging.", CLIN CANCER RES., vol. 15, no. 21, 2009, pages 6674 - 6682, XP055073098
KASSIS ET AL.: "Isolation of mesenchymal stem cells from G-CSF mobilized human peripheral blood using fibrin microbeads.", BONE MARROW TRANSPLANT., vol. 37, no. 10, 2006, pages 967 - 976, XP055044142
CHENG ET AL.: "Inhibition of VEGF-Dependent Multistage Carcinogenesis by Soluble EphA Receptors.", NEOPLASIA, vol. 5, no. 5, 2003, pages 445 - 456, XP002493164
See also references of EP 2582388A4
VEARING ET AL.: "Concurrent Binding of Anti-EphA3 Antibody and Ephrin-A5 Amplifies EphA3 Signaling and Downstream Responses: Potential as EphA3-Specific Tumor-Targeting Reagents.", CANCER RES., vol. 65, no. 15, 1 August 2005 (2005-08-01), pages 6745 - 6754, XP002493162
O'CONNOR ET AL.: "Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging.", CLIN CANCER RES., vol. 15, no. 21, 2009, pages 6674 - 6682, XP055073098
KASSIS ET AL.: "Isolation of mesenchymal stem cells from G-CSF mobilized human peripheral blood using fibrin microbeads.", BONE MARROW TRANSPLANT., vol. 37, no. 10, 2006, pages 967 - 976, XP055044142
CHENG ET AL.: "Inhibition of VEGF-Dependent Multistage Carcinogenesis by Soluble EphA Receptors.", NEOPLASIA, vol. 5, no. 5, 2003, pages 445 - 456, XP002493164
See also references of EP 2582388A4
Attorney, Agent or Firm:
LOCKYER, Jean, M. et al. (Two Embarcadero Center Eighth Floo, San Francisco California, US)
Download PDF: